Centre de Recherche Cancérologie-Immunologie Nante
|
Dr. Lisa Oliver is biologist at the University Hospital of Nantes. She received her first PhD at the University of Cape Town and then a second PhD at the University of Pierre and Marie, France in 1991. She joined the Department of Cell Biology of NYU Medical Center (NY, NY. USA) as a post-doc (1987-1989). She is presently setting up the 3D bioprinting at the “Centre de Recherche Cancerologie-Immunologie Nantes-Angers” using as model the Glioblastoma Multiforme type IV tumors. At present, she has a collection of about 80 primary tumor cultures, which are being exploited for capacity to form 3D tumors in vitro. She has received the diamond trophy from Cellink (an international company) as a collaborative partner for outstanding innovative bioprinting work. She is the author of 88 publications since 1989 (32 publications for the 2012-2017 period) with a H-index of 30 for 2500 citations. |
-
Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma
Cell Death & Disease 11, 19 (2020)
M. Rabe, S. Dummont, A. Álvarez-Arenas Alcami, H. Janati, J. Belmonte-Beitia, G.F. Calvo, C. Thibault-Charpentier, Q. Séry, C. Chauvin, N. Joalland, F. Briand, E. Scotet, C. Pecqueur, J. Clairambault, L. Oliver, A. Nadaradjane, V.M. Pérez-García, P. François Cartron, C. Gratas, F.M. Vallette -
Mitochondria transfer from tumor-activated stromal cells (TASCs) to primary Glioblastoma cells.
Biochemical and Biophysical Research Communications 533(1) 139-147 (2020)
C. Salaud, A. Alvarez-Arenas Alcami, F. Geraldo, J. Belmonte-Beitia, G.F. Calvo, C. Gratas, C. Pecqueur, D. Garnier, V.M. Pérez- García, F.M. Vallette, L. Oliver
Dr. Lisa Oliver is biologist at the University Hospital of Nantes. She received her first PhD at the University of Cape Town and then a second PhD at the University of Pierre and Marie, France in 1991. She joined the Department of Cell Biology of NYU Medical Center (NY, NY. USA) as a post-doc (1987-1989). She is presently setting up the 3D bioprinting at the “Centre de Recherche Cancerologie-Immunologie Nantes-Angers” using as model the Glioblastoma Multiforme type IV tumors. At present, she has a collection of about 80 primary tumor cultures, which are being exploited for capacity to form 3D tumors in vitro. She has received the diamond trophy from Cellink (an international company) as a collaborative partner for outstanding innovative bioprinting work. She is the author of 88 publications since 1989 (32 publications for the 2012-2017 period) with a H-index of 30 for 2500 citations. |
- Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma
Cell Death & Disease 11, 19 (2020)
M. Rabe, S. Dummont, A. Álvarez-Arenas Alcami, H. Janati, J. Belmonte-Beitia, G.F. Calvo, C. Thibault-Charpentier, Q. Séry, C. Chauvin, N. Joalland, F. Briand, E. Scotet, C. Pecqueur, J. Clairambault, L. Oliver, A. Nadaradjane, V.M. Pérez-García, P. François Cartron, C. Gratas, F.M. Vallette - Mitochondria transfer from tumor-activated stromal cells (TASCs) to primary Glioblastoma cells.
Biochemical and Biophysical Research Communications 533(1) 139-147 (2020)
C. Salaud, A. Alvarez-Arenas Alcami, F. Geraldo, J. Belmonte-Beitia, G.F. Calvo, C. Gratas, C. Pecqueur, D. Garnier, V.M. Pérez- García, F.M. Vallette, L. Oliver